{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:57Z","timestamp":1794047457183,"version":"4.8.0"},"reference-count":27,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"6","license":[{"start":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T00:00:00Z","timestamp":1701302400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Venetoclax is a standard treatment for patients with chronic lymphocytic leukemia (CLL) following covalent Bruton tyrosine kinase inhibitor (cBTKi) therapy, despite relatively limited prospective data in this setting. Pirtobrutinib is a highly selective, non-covalent (reversible) BTKi that was designed to overcome the pharmacologic limitations of cBTKi and re-establish BTK inhibition. An unanchored matching-adjusted indirect comparison (MAIC) was conducted to estimate the treatment effect of pirtobrutinib versus venetoclax monotherapy in patients with cBTKi-pretreated CLL. Data from patients with CLL who were venetoclax-na\u00efve and pretreated with cBTKi received pirtobrutinib (N=146) in the phase I\/II BRUIN study were compared with the only identified trial of patients with CLL receiving venetoclax after a cBTKi (N=91), as administered as monotherapy until progression. Outcomes included progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and treatment-emergent adverse events. Both unweighted and weighted analyses were conducted. PFS and OS of pirtobrutinib and venetoclax were comparable in both unweighted and weighted analyses (weighted hazard ratios for PFS: 1.01, 95% confidence interval [CI]: 0.58-1.73, P=0.98 and OS: 0.64, 95% CI: 0.25-1.67, P=0.34). ORR was significantly higher for pirtobrutinib (80.2% vs. 64.8%, P=0.01). Grade \u22653 treatment-emergent adverse events were lower in weighted analyses for pirtobrutinib versus venetoclax (all P&lt;0.01), except for pneumonia, which was similar. These results suggest that pirtobrutinib may also be considered as an effective and well-tolerated treatment for patients with relapsed CLL following cBTKi.<\/jats:p>","DOI":"10.3324\/haematol.2023.284150","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T03:40:13Z","timestamp":1701315613000},"page":"1866-1873","source":"Crossref","is-referenced-by-count":5,"title":["Pirtobrutinib &lt;i&gt;versus&lt;\/i&gt; venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: a matching-adjusted indirect comparison"],"prefix":"10.3324","volume":"109","author":[{"given":"Othman","family":"Al-Sawaf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Hua","family":"Jen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiewen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Goebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Pagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarang","family":"Abhyankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Davids","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby A.","family":"Eyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,11,30]]},"reference":[{"key":"62146","doi-asserted-by":"crossref","unstructured":"Roeker LE, Mato AR. Approaches for relapsed CLL after chemotherapy-free frontline regimens. Hematology Am Soc Hematol Educ Program. 2020; 2020(1):10-17.","DOI":"10.1182\/hematology.2020000168"},{"key":"62147","unstructured":"NCCN. NCCN Clinical Practice Guidelines in Oncology: CLL\/SLL Version 2.2023. 2023. Publisher Full Text|"},{"key":"62148","doi-asserted-by":"crossref","unstructured":"Seymour JF, Kipps TJ, Eichhorst BF. Four-year analysis of Murano study confirms sustained benefit of time-limited venetoclax-rituximab (VenR) in relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL). Blood. 2019; 134(Suppl 1):355.","DOI":"10.1182\/blood-2019-123930"},{"key":"62149","doi-asserted-by":"crossref","unstructured":"Seymour JF, Kipps TJ, Eichhorst BF. Enduring undetectable MRD and updated outcomes in relapsed\/ refractory CLL after fixed-duration venetoclax-rituximab. Blood. 2022; 140(8):839-850.","DOI":"10.1182\/blood.2021015014"},{"key":"62150","doi-asserted-by":"crossref","unstructured":"Eyre TA, Kirkwood AA, Gohill S. Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis. Br J Haematol. 2019; 185(4):656-669.","DOI":"10.1111\/bjh.15802"},{"key":"62151","doi-asserted-by":"crossref","unstructured":"Mato AR, Nabhan C, Barr PM. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. Blood. 2016; 128(18):2199-2205.","DOI":"10.1182\/blood-2016-05-716977"},{"key":"62152","doi-asserted-by":"crossref","unstructured":"Hampel PJ, Rabe KG, Call TG. Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib. Blood Cancer J. 2022; 12(9):124.","DOI":"10.1038\/s41408-022-00721-6"},{"key":"62153","doi-asserted-by":"crossref","unstructured":"Roberts AW, Seymour JF, Eichhorst B. Pooled multi-trial analysis of venetoclax efficacy in patients with relapsed or refractory chronic lymphocytic leukemia. Blood. 2016; 128(22):3230.","DOI":"10.1182\/blood.V128.22.3230.3230"},{"key":"62154","doi-asserted-by":"crossref","unstructured":"Jones JA, Mato AR, Wierda WG. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018; 19(1):65-75.","DOI":"10.1016\/S1470-2045(17)30909-9"},{"key":"62155","doi-asserted-by":"crossref","unstructured":"Fischer K, Al-Sawaf O, Hallek M. Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2020; 2020(1):357-362.","DOI":"10.1182\/hematology.2020000120"},{"key":"62156","unstructured":"Lilly. Jaypirca (pirtobrutinib) prescribing information. 2023. Publisher Full Text|"},{"key":"62157","doi-asserted-by":"crossref","unstructured":"Wang ML, Jurczak W, Zinzani PL. Pirtobrutinib in covalent BTK-inhibitor pretreated mantle cell lymphoma. J Clin Oncol. 2023; 41(24):3988-3997.","DOI":"10.1200\/JCO.23.00562"},{"key":"62158","doi-asserted-by":"crossref","unstructured":"Mato AR, Woyach JA, Brown JR. Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia. N Engl J Med. 2023; 389(1):33-44.","DOI":"10.1056\/NEJMoa2300696"},{"key":"62159","doi-asserted-by":"crossref","unstructured":"Signorovitch JE, Sikirica V, Erder MH. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012; 15(6):940-947.","DOI":"10.1016\/j.jval.2012.05.004"},{"key":"62160","doi-asserted-by":"crossref","unstructured":"Greenland S, Morgenstern H. Ecological bias, confounding, and effect modification. Int J Epidemiol. 1989; 18(1):269-274.","DOI":"10.1093\/ije\/18.1.269"},{"key":"62161","doi-asserted-by":"crossref","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Making. 2018; 38(2):200-211.","DOI":"10.1177\/0272989X17725740"},{"key":"62162","doi-asserted-by":"crossref","unstructured":"Guyot P, Ades A, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012; 12:9.","DOI":"10.1186\/1471-2288-12-9"},{"key":"62163","doi-asserted-by":"crossref","unstructured":"Signorovitch JE, Wu EQ, Yu AP. Comparative effectiveness without head-to-head trials. Pharmacoeconomics. 2010; 28(10):935-945.","DOI":"10.2165\/11538370-000000000-00000"},{"key":"62164","doi-asserted-by":"crossref","unstructured":"Jiang Y, Ni W. Performance of unanchored matching-adjusted indirect comparison (MAIC) for the evidence synthesis of singlearm trials with time-to-event outcomes. BMC Med Res Methodol. 2020; 20(1):241.","DOI":"10.1186\/s12874-020-01124-6"},{"key":"62165","doi-asserted-by":"crossref","unstructured":"Eyre TA, Hess LM, Sugihara T. Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States: a real-world database study. Leuk Lymphoma. 2023; 65(5):1005-1016.","DOI":"10.1080\/10428194.2023.2190436"},{"key":"62166","doi-asserted-by":"crossref","unstructured":"Seymour JF, Kipps TJ, Eichhorst B. Venetoclax\u2013rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018; 378(12):1107-1120.","DOI":"10.1056\/NEJMoa1713976"},{"key":"62167","doi-asserted-by":"crossref","unstructured":"Thompson MC, Coombs CC, Roeker LE. Outcomes of therapies and resistance mutations following non-covalent Bruton\u2019s tyrosine kinase inhibitor treatment for patients with chronic lymphocytic leukemia and richter transformation. Blood. 2022; 140(Suppl 1):9885-9888.","DOI":"10.1182\/blood-2022-159133"},{"key":"62168","doi-asserted-by":"crossref","unstructured":"Wong EC, Dulai PS, Marshall JK, Jairath V, Reinisch W, Narula N. Matching-adjusted Indirect comparisons vs propensity score matching with individual patient-level data to estimate treatment efficacy. Inflamm Bowel Dis. 2024; 30(2):311-313.","DOI":"10.1093\/ibd\/izad077"},{"key":"62169","doi-asserted-by":"crossref","unstructured":"Signorovitch J, Diels J, Van Sanden S. Matching-adjusted indirect comparison (MAIC) results confirmed by head-to-head trials: a case study in psoriasis. J Dermatolog Treat. 2023; 34(1):2169574.","DOI":"10.1080\/09546634.2023.2169574"},{"key":"62170","doi-asserted-by":"crossref","unstructured":"Phillippo DM, Dias S, Elsada A, Ades A, Welton NJ. Population adjustment methods for indirect comparisons: a review of national institute for health and care excellence technology appraisals. Int J Technol Assess Health Care. 2019; 35(3):221-228.","DOI":"10.1017\/S0266462319000333"},{"key":"62171","doi-asserted-by":"crossref","unstructured":"Davids MS, Telford C, Abhyankar S, Waweru C, Ringshausen I. Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-na\u00efve chronic lymphocytic leukemia. Leuk Lymphoma. 2021; 62(10):2342-2351.","DOI":"10.1080\/10428194.2021.1913144"},{"key":"62172","doi-asserted-by":"crossref","unstructured":"Sk\u00e5nland SS, Brown JR. PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here?. Haematologica. 2023; 108(1):9-21.","DOI":"10.3324\/haematol.2022.281266"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284150\/76376","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284150\/77066","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11364\/76376","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:18Z","timestamp":1794045918000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.284150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,30]]},"references-count":27,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.284150","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,30]]}}}